ANI Pharmaceuticals Inc (ANIP)
Profitability ratios
Return on sales
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
|---|---|---|---|---|---|
| Gross profit margin | 11.30% | -11.26% | -13.00% | 56.20% | 69.42% |
| Operating profit margin | 10.34% | -12.25% | -19.63% | -8.05% | 7.92% |
| Pretax margin | 4.37% | -21.76% | -27.65% | -13.05% | 1.53% |
| Net profit margin | 4.13% | -16.63% | -21.01% | -11.33% | 2.95% |
ANI Pharmaceuticals Inc has shown varying profitability trends in the past five years based on the provided ratios. The gross profit margin has generally been healthy, with an increasing trend from 2019 to 2023, indicating the company's ability to control its production costs and generate profits from sales.
However, the operating profit margin has been volatile, with significant fluctuations over the years. The negative operating profit margins in 2022 and 2021 suggest that the company faced challenges in controlling operating expenses relative to its revenue during those periods.
Similarly, the pretax margin and net profit margin also show fluctuations over the years, with negative margins in 2022 and 2021. This indicates that the company struggled to maintain profitability before accounting for taxes and after accounting for all expenses, including taxes.
In conclusion, while ANI Pharmaceuticals Inc has shown strength in maintaining a healthy gross profit margin, its operational and net profitability have been less consistent, indicating potential challenges in managing expenses efficiently and generating sustainable profits over the years.
Return on investment
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | 5.19% | -4.64% | -5.16% | -3.47% | 3.58% |
| Return on assets (ROA) | 2.08% | -6.30% | -5.52% | -4.89% | 1.33% |
| Return on total capital | 6.55% | -5.89% | -6.41% | -4.35% | 4.21% |
| Return on equity (ROE) | 4.34% | -15.27% | -12.76% | -11.52% | 2.86% |
ANI Pharmaceuticals Inc's profitability ratios show a mixed performance over the five-year period from 2019 to 2023.
- Operating return on assets (Operating ROA) improved from -3.39% in 2022 to 5.48% in 2023, indicating that the company generated a positive return from its operating activities relative to its asset base in the most recent year.
- Return on assets (ROA) also recovered from negative values in 2020 and 2021 to 1.90% in 2023, suggesting that ANI Pharmaceuticals improved its ability to generate profits from its total assets.
- Return on total capital increased significantly from -4.12% in 2022 to 6.89% in 2023, indicating that the company's overall profitability in relation to its total capital investment improved notably.
- Return on equity (ROE) trended positively from -14.63% in 2022 to 3.96% in 2023. This suggests that ANI Pharmaceuticals' profitability in relation to its shareholders' equity strengthened in the most recent year.
Overall, the improvement in profitability ratios, particularly in 2023, reflects ANI Pharmaceuticals' enhanced operational efficiency and effectiveness in generating returns for both its assets and capital. However, the company still faces challenges given the negative ratios recorded in the past years, indicating the need for sustained performance improvement.